	Patient Population	Pre-clinical	Phase 1/2	Phase 3	Regulatory Approval
Setmelanotide *daily formulation*	POMC, PCSK1 or LEPR deficiency		US, Canada*		
	Bardet-Biedl syndrome		US, Canada*		
Setmelanotide *daily formulation*	Hypothalamic obesity		Enrollment complete		
	Emanate Obesity and Hunger Clinical Trial				
	Pediatrics (age 2 to <6 years, biallelic POMC, PCSK1, or LEPR deficiency or Bardet-Biedl syndrome)				
	Daybreak Obesity and Hunger Clinical Trial				
Setmelanotide *weekly formulation*	Switch study with patients previously on setmelanotide				
LB54640	Hypothalamic obesity				
RM-718	Rare MC4R pathway diseases		Ph1 trial 1H2024		
Pre-clinical	Congenital Hyperinsulinism (CHI)	Lead identification underway			

Complete Denotes trial underway Denotes planned trial

*Other countries include EU, Great Britain, Israel

LEPR, leptin receptor; MC4R, melanocortin-4 receptor; PCSK1, proprotein convertase subtilisin/kexin type 1; POMC, proopiomelanocortin.